Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis
Authors:
- Diane S. AbouDADiane S. Abou
- David UlmertDUDavid Ulmert
- Michele DoucetMDMichele Doucet
- Robert F. HobbsRHRobert F. Hobbs
- Ryan C. RiddleRRRyan C. Riddle
- Daniel L. J. ThorekDTDaniel L. J. Thorek
Open Access
- 17 December 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 108 (5)
Abstract
Bone-metastatic, castration-resistant prostate cancer (bmCRPC) represents a lethal stage of the most common noncutaneous cancer in men. The recent introduction of Radium-223 dichloride, a bone-seeking alpha particle (α)–emitting radiopharmaceutical, demonstrates statistically significant survival benefit and palliative effect for bmCRPC patients. Clinical results have established safety and efficacy, yet questions remain regarding pharmacodynamics and dosing for optimized patient benefit. We elucidated the biodistribution of 223 Ra as well as interaction with the bone and tumor compartments in skeletally mature mice (C57Bl/6 and CD-1, n = 3–6) and metastasis models (LNCaP and PC3, n = 4). Differences in uptake were evaluated by µCT and histological investigation. Novel techniques were leveraged on whole-mount undecalcified cryosections to determine microdistribution of Radium-223. All statistical tests were two-sided. 223 Ra uptake in the bones (>30% injected activity per gram) at 24 hours was also accompanied by non-negligible remnant activity in the kidney (2.33% ± 0.36%), intestines (5.73% ± 2.04%), and spleen (10.5% ± 5.9%) Skeletal accumulation across strains did not correspond with bone volume or surface area but instead to local blood vessel density ( P = .04). Microdistribution analysis by autoradiography and α camera revealed targeting of the ossifying surfaces adjacent to the epiphyseal growth plate. In models of PCa metastasis, radioactivity does not localize directly within tumors but instead at the apposite bone surface. Osteoblastic and lytic lesions display similar intensity, which is comparable with uptake at sites of normal bone remodeling. Profiling the macro- and microdistribution of 223 Ra in healthy and diseased models has important implications to guide precision application of this emerging α-therapy approach for bmCRPC and other bone metastastic diseases.Keywords
This publication has 26 references indexed in Scilit:
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- A bone marrow toxicity model for223Ra alpha-emitter radiopharmaceutical therapyPhysics in Medicine & Biology, 2012
- Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific AntigenCancer Discovery, 2012
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialThe Lancet, 2012
- Radioisotopes for metastatic bone pain2011
- Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006Prostate Cancer and Prostatic Diseases, 2011
- The α-Camera: A Quantitative Digital Autoradiography Technique Using a Charge-Coupled Device for Ex Vivo High-Resolution Bioimaging of α-ParticlesJournal of Nuclear Medicine, 2010
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Dose to Endosteal Cells and Relative Distribution Factors for Radium-224 and Plutonium-239 Compared to Radium-226Health Physics, 1978
- Comparative uptake and elution of45Ca,85Sr,133Ba and223Ra in bone powderCalcified Tissue International, 1967